| ²é¿´: 2752 | »Ø¸´: 2 | |||
liu1983660½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
Å·ÖÞÒ©µä2.9.5 ºÍ2.9.40
|
|
Çë¿öÅ·ÖÞÒ©µä2.9.5uniformity of mass of single-dose preparations ºÍ2.9.40uniformity of dosage unitsµÄÇø±ð£¿ 2.9.40uniformity of dosage unitsÖÐÓÐuniformity contentº¬Á¿¾ùÔȶȺÍmass variation×°Á¿²îÒì 2.9.5uniformity of mass of single-dose preparations ÊÇÊ²Ã´ÄØ£¿ |
» ²ÂÄãϲ»¶
°ÍÀèÈø¿ËÀ×´óѧÓë¹ú¼ÒÁôѧ»ù½ðίºÏ×÷²©Ê¿Ñо¿ÉúÏîÄ¿-Ö¬ÖÊÄÉÃ×Ò©Îï/ÉúÎï²ÄÁÏ/¶à·ÓµÝËÍ
ÒѾÓÐ10È˻ظ´
2026Äêɽ¶«´óѧº£ÑóѧԺÉúÎïÓëÒ½Ò©²©Ê¿ÕÐÉú-Àîϼ¿ÎÌâ×é
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ223È˻ظ´
²©Ê¿Ñо¿ÉúÕÐÉú
ÒѾÓÐ0È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ2È˻ظ´
26É격×Ô¼ö
ÒѾÓÐ12È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
×îаæÅ·ÖÞÒ©µäEP7.0
ÒѾÓÐ24È˻ظ´
ÇóÖú ×îÐÂÅ·ÖÞÒ©µä EP7.0 ºÍÃÀ¹úÒ©µä USP34 ÏÂÔØ×ÊÔ´
ÒѾÓÐ10È˻ظ´
ÇóÖúÅ·ÖÞÒ©µä£¬ÃÀ¹úÒ©µäÖÐÓÐ×϶¡ÏãÜÕÂð£¿
ÒѾÓÐ7È˻ظ´
¾«»ª£¡×îÐÂÅ·ÖÞÒ©µäEP7.0
ÒѾÓÐ75È˻ظ´
¡¾ÇóÖú¡¿ÄÄλ¸ßÊÖ°ïæ²éһ϶ò±´É³Ì¹IrbesartanµÄÅ·ÖÞÒ©µä
ÒѾÓÐ5È˻ظ´
ÇóÖúÅ·ÖÞÒ©µäEP6.0ĪÎ÷ɳÐDz¿·Ö
ÒѾÓÐ7È˻ظ´
¡¾·ÖÏí¡¿Å·ÖÞÒ©µäÖÊÁ¿±ê×¼Æð²ÝÖ¸ÄÏ£¨Ó¢Îİ棩 ÖµµÃ¿´£¡
ÒѾÓÐ122È˻ظ´
gtyhlag
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
»¯Ñ§´ô×Ó
- Ó¦Öú: 4 (Ó×¶ùÔ°)
- ½ð±Ò: 37048.5
- É¢½ð: 1200
- ºì»¨: 6
- Ìû×Ó: 5096
- ÔÚÏß: 1142.8Сʱ
- ³æºÅ: 131725
- ×¢²á: 2005-12-12
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï
warlen(½ð±Ò+2): ллӦÖú 2011-06-21 14:50:34
warlen(½ð±Ò+2): ллӦÖú 2011-06-21 14:50:34
|
Å·ÖÞÒ©µä7.0Öеģ» Çë¿´¸½¼þ£º |
2Â¥2011-06-07 13:32:03
liu1983660
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1161.5
- ºì»¨: 1
- Ìû×Ó: 52
- ÔÚÏß: 13.2Сʱ
- ³æºÅ: 254351
- ×¢²á: 2006-05-27
- רҵ: É«Æ×·ÖÎö
3Â¥2011-06-08 11:23:13














»Ø¸´´ËÂ¥